Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients

International Journal of Cancer

Volumn 105, Issue 3, 2003, Pages 361-370

  Beau Faller, Michèle ^a   Gaub, Marie Pierre ^a   Schneider, Anne ^a   Ducrocq, Xavier ^b   Massard, Gilbert ^b   Gasser, Bernard ^b   Chenard, Marie Pierre ^a   Kessler, Romain ^a   Anker, Philippe ^c   Stroun, Maurice ^c   Weitzenblum, Emmanuel ^a   Pauli, Gabrielle ^a   Wihlm, Jean Marie ^b   Quoix, Elisabeth ^b   Oudet, Pierre ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b HÔPITAL CIVIL   (France)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Histologic type; Lung cancer; Microsatellite analysis; Plasma DNA alterations; Prognosis

Indexed keywords

MICROSATELLITE DNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 20Q; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 9P; CHROMOSOME 9Q; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MICROSATELLITE MARKER; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CHROMOSOME MAPPING; DISEASE PROGRESSION; DNA; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0038326550     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11079     Document Type: Article

References (61)

1. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, eds. Histological typing of lung and pleura. In: Sobin LH. World Health Organization International classification of tumors, 3rd ed. New York: Springer Verlag, 1999.
2. El-Torky M, El-Zeky F, Hall JC. Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases. Cancer 1999;65:2361-9.
3. Livingston, RB. Combined modality therapy of lung cancer. Clin Cancer Res 1997;3:2638-47.
4. Adjei AA, Marks RS, Bonner JA. Current guidelines for the management of small-cell lung cancer. Mayo Clin Proc 1999;74:809-16.
5. Non-Small Cell Lung Cancer Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
6. Kohno H, Hiroshima K, Toyozaki T, Fujisawa T, Ohwada H. p53 mutations and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with non-small cell lung carcinoma. Cancer 1999;85:341-7.
7. Mao L, Lee DJ, Tokmann MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 1999;91:9871-5.
8. Pylkkänen L, Karjalainen A, Antitila S, Vainio H, Husgafvel-Pärsiainen K. No evidence of microsatellite instability but frequent loss of heterozygosity in primary resected lung cancer. Environ Mol Mutagen 1997;30:217-23.
9. Neuville EM, Stewart MP, Swift A, Liloglou T, Ross H, Gosney JR, Doneely RJ, Field JK. Allelotype of non-small cell lung cancer. Int J Oncol 1996;9:533-9.
10. Endo C, Sagawa M, Sato M, Chen Y, Sakurada A, Aikawa H, Takahashi S, Usuda K, Saito Y, Fujimura S. Sequential loss of heterozygosity in the progression of squamous cell carcinoma of the lung. Br J Cancer 1998;78:612-5.
11. Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, Hong WK, Mao L. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6:559-65.
12. Tomizawa Y, Adachi J, Kohno T, Hamada K, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Yokota J. Prognostic significance of allelic imbalance on chromosome 9p in stage I non-small cell lung carcinoma. Clin Cancer Res 1999;5:1139-46.
13. Sasatomi E, Finkelstein SD, Woods JD, Bakker A, Swalskt PA, Luketcih JD, Fernando HC, Yousem SA, Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Cancer Res 2002;62:2681-9.
14. Michelland S, Gazzeri S, Brambilla E, Robert-Nicoud M. Comparison of chromosomal imbalances in neuro-endocrine and non-small-cell lung carcinomas. Cancer Genet Cytogenet 1999;114:22-30.
15. Virmani AK, Fong KW, Kodagoda D, McIntire D, Hung J, Tonk V, Minna J, Gadzar AF. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998;21:308-19.
16. Kohno T, Yokota J. How many tumor suppressor gene are involved in human lung carcinogenesis? Carcinogenesis 1999;20:1403-10.
17. Pei J, Balsara BR, Li S, Gabrielson E, Feder M, Jen J, Testa JR. Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 2001;31:282-7.
18. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer 1977;37:646-50.
19. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999;18:65-73.
20. Anker P, Lyautey J, Lederrey C, Stroun M. Circulating nucleic acids in plasma or serum. Clin Chim Acta 2001;313:143-6.
21. Goessl C, Müller M, Straub B, Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 2002;41:668-76.
22. Fleischhacker M. First international symposium on circulating nucleic acids in plasma/serum. Implications in cancer diagnostics, prognosis or follow-up and in prenatal diagnosis. Eur J Med Res 1999;22:488-9.
23. Anker P, Stroun M. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia 2001;15:289-91.
24. Goessl C, Krause H, Müller M, Heicappel R, Schrader M, Sachsinger J, Miller K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941-5.
25. Wong TS, Chang HW, Tang KC, Wei WI, Kwong DL, Sham JS, Yuen AP, Kwong YL. High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin Cancer Res 2002;8:433-7.
26. von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A, Hofman R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2001;94:67-72.
27. Von Knobloch R, Hegele A, Wille S, Heidenreich A, Hofmann R. Microsatellite analysis detects high incidence of serum-DNA-alterations in renal cell carcinoma. Eur Urol 2001;39(Suppl 5):187.
28. Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033-4.
29. Sanchez-Cespedez M, Monzo M, Rosell R, Pifarre A, Calvo R, Lopez-Cabreizo MP, Astudillo J. Detection of chromosome 3p alterations in serum DNA of non-small cell lung cancer patients. Ann Oncol 1998;9:113-6.
30. Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino H. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999;5:2689-92.
31. Gonzales R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ, Stroun M, Provencio M, Espana P, Anker P, Bonilla F. Microsatellite alteration and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol 2000;11:1097-104.
32. Bruhn N, Beinert T, Oehm C, Jandrig B, Petersen I, Chen XQ, Possinger K, Fleishhacker M. Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann NY Acad Sci 2000;906:72-82.
33. Allan JM, Hardie LJ, Briggs JA, Davidson LA, Watson JP, Pearson SB, Muers MF, Wild CP. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer. Int J Cancer 2001;91:359-65.
34. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA, Tavecchoi L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-8.
35. Esteller M, Sanchez-Cespedez M, Rosell R, Sidransky D, Baylin SB, Herman GH. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
36. Usadel H, Brabender J, Danenberg KD, Jéronimo C, Harden S, Engles S, Danenberg PV, Yang S, Sidransky D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371-5.
37. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973;4:41-2.
38. Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1710-7.
39. Schneider A, Borgnat S, Lang H, Régine O, Lindner V, Kassem M, Saussine C, Oudet P, Jacqmin D, Gaub MP. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 2000;60:4617-22.
40. Cave-Riant F, Cuillerier B, Beau-Faller M, Picard E, Vidili R, Martinet A, Alla F, Bronner C, Schneider A, Oudet P, Gaub M-P. Association of genetic defects in primary resected lung adenocarcinoma revealed by targeted allelic imbalance analysis. Am J Respir Cell Mol Biol 2002;4:495-502.
41. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1976;35:1-39.
42. Liloglou T, Maloney P, Xinarianos G, Fear S, Field J. Sensitivity and limitations of high throughput fluorescent microsatellite analysis for the detection of allelic imbalance: application in lung tumors. Int J Oncol 2000;16:5-14.
43. Fujiwara Y, Chi DDJ, Wang H, Keleman P, Morton D, Turner R, Hoon DSB. Plasma DNA microsatellite as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 1999;59:1567-71.
44. Hibi K, Robinson R, Booker S, Wu L, Hamilton SR, Sidransky D, Jen J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998;58:1405-7.
45. Utting M, Werner W, Dahse R, Schubert J, Junker K. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res 2002;8:35-40.
46. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueava MJ, Navarro F, Provencio M, San Martin S, Espana P, Bonilla F. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999;59:3251-6.
47. Silva JM, Bonilla F. Correspondence re: F Coulet et al., detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2001;61:8565-96.
48. Cooper CA, Bubb VJ, Smithson RL, Carter S, Gledhill S, Lamb D, Wyllie AH, Carey FA. Loss of heterozygosity at 5q21 in non-small cell lung cancer: a frequent event but without evidence of apc mutation. J Pathol 1996;180:33-7.
49. Sanz-Ortega J, Bryant B, Sanz-Esponera J, Asenjo LA, Saez MC, Torres A, Balibrea JL, Sobel M, Merino MJ. LOH at the APC/MCC gene (5q21) is frequent in early stage of non-small cell lung cancer. Pathol Res Pract 1999;195:677-80.
50. Bradender J, Usadel H, Daneneberg KD, Metzger R, Schneider PM, Lord RV, Wickramashinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001;27:3528-32.
51. Petersen S, Aninat-Meyer M, Schlüns K, Gellert K, Dietel M, Petersen I. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas on the lung. Br J Cancer 2000;82:65-73.
52. Goeze A, Schluns K, Wolf G, Thasler Z, Pertersen S, Petersen J. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J Pathol 2002;196:8-16.
53. Martinet N, Alla F, Farré G, Labib T, Drouot H, Vidili R, Picard E, Gaub MP, Le Faou D, Siat J, Borell J, Vermylen P, et al. Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursors lesions. Cancer Res 2000;60:2869-75.
54. Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B Coca S, Provencio M, Espana P, Bonilla F. Persistence of tumor DNA in plasma DNA of breast cancer patients after mastectomy. Ann Surg Oncol 2002;9:71-6.
55. Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DSB. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001;61:5723-6.
56. Aoyagi Y, Yokose T, Minami Y, Ochiai A, Iijima T, Morishita Y, Oda T, Fukao K, Nogushi M. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res 2001;21:7950-4.
57. Fey MF, Tobler A. Tumor heterogeneity and clonality - an old theme revisited. Ann Oncol 1996;7:121-8.
58. Garcia JM, Silva JM, Dominguez G, Silva J, Bonilla F. Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations. Genes Chromosomes Cancer 2001;31:300-1.
59. Fournié GJ, Courtin JP, Laval F, Chalé JJ, Pourrat JP, Pujazon MC, Lauqye D, Carles P. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995;91:221-7.
60. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence of their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
61. Stroun M, Lyautey J, Lederrey C, Mulcahy HE, Anker P. Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA. Ann NY Acad Sci 2001;945:258-64.